Recurrence of primary biliary cirrhosis after liver transplantation

Salguero, O. Oria de Rueda; Moreno, José María Ruiz; Seijas, M Couselo; Rubio, Elena Múñez; Salas, Clara; Laporta, Rosalía; Cuervas-Mons, Valentín

doi:10.1016/s0041-1345(03)00064-2

Cited by 11 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, overall survival of 89% after LT was similar to that seen in patients receiving transplants for each autoimmune liver disease (AIH, PBC or PSC) . The 5‐year overall patient survival for AIH, PBC and PSC was 70%, 87% and 89%, respectively; and the 10‐year survival post‐LT was 70%, 76% and 80% for AIH, PBC and PSC, respectively (Table ); these results are similar with those reported by other centres .…”

Section: Discussionsupporting

confidence: 86%

“…Approximately, one of four liver transplantations is performed for autoimmune liver diseases, and recurrence of disease after liver transplantation (LT) is a recognized entity . The prevalence of recurrent disease tends to increase with time following LT and 5 years post‐LT, the frequency of recurrent disease has been reported to range from 17 to 42% in patients with AIH, 12 to 13% in those with PBC and 12 to 60% in subjects with PSC . As overlap syndromes are uncommon, studies documenting outcomes for recurrent disease post‐LT in this population are lacking.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liver transplantation for overlap syndromes of autoimmune liver diseases

Bhanji¹,

Mason²,

Girgis

et al. 2012

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Liver transplantation for overlap syndromes of autoimmune liver diseases

Bhanji¹,

Mason²,

Girgis

et al. 2012

Liver International

View full text Add to dashboard Cite

show abstract

“…Despite these excellent survival data after OLT, Neuberger et al (7) reported for the first time in 1982 on PBC recurrence in the allograft after OLT. Since then, several studies confirmed these results, with recurrence rates between 8 and 32% (3,8,11,14). However, histological diagnosis of PBC is difficult: even experienced pathologists cannot always differentiate between PBC recurrence and chronic rejection, biliary obstruction, graft-versus-host disease, ischaemic lesions or drug-induced graft injury.…”

Section: Discussionmentioning

confidence: 83%

Long‐term follow‐up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients

Jacob

Neumann

Bahra

et al. 2006

Clinical Transplantation

109

View full text Add to dashboard Cite

Orthotopic liver transplantation (OLT) is the only effective curative therapy for end-stage primary biliary cirrhosis (PBC). Survival after OLT is excellent, although recent data have shown a recurrence rate of PBC of up to 32% after transplantation. The aim of this study is to investigate the course after disease recurrence, particularly with regard to liver function and survival in a long-term follow-up. Between April 1989 and April 2003, 1,553 liver transplantations were performed in 1,415 patients at the Charité, Virchow Clinic. Protocol liver biopsies were taken after one, three, five, seven, 10 and 13 yr. One hundred (7%) patients suffered from histologically proven PBC. Primary immunosuppression consisted of cyclosporine (n = 54) or tacrolimus (Tac) (n = 46). Immediately after OLT, all patients received ursodeoxycholic acid. Corticosteroids were withdrawn three to six months after OLT. The median age of the 85 women and 15 men was 55 yr (range 25-66 yr). The median follow-up after liver transplantation was 118 months (range 16-187 months) and after recurrence 30 months (range 4-79 months). Actuarial patient survival after five, 10 and 15 yr was 87, 84 and 82% respectively. Ten patients (10%) died after a median survival time of 32 months. Two of these patients developed organ dysfunction owing to recurrence of PBC. Histological recurrence was found in 14 patients (14%) after a median time of 61 months (range 36-122 months). Patients with Tac immunosuppression developed PBC recurrence more often (p < 0.05) and also earlier (p < 0.05). Fifty-seven patients developed an acute rejection and two patients a chronic rejection episode. Liver function did not alter within the first five yr after histologically proven PBC recurrence. Multivariate analysis of the investigated patients showed that the recipient's age and Tac immunosuppression were significant risk factors for PBC recurrence. Long-term follow-up of up to 15 yr after liver transplantation, owing to PBC, in addition to maintenance of liver function, shows excellent organ and patient survival rates. Although protocol liver biopsies revealed histological recurrence in 14 (14%) patients, only two patients developed graft dysfunction. Tac-treated patients showed more frequently and also earlier histologically proven PBC recurrence; however, in our population we could not observe an impact on graft dysfunction and patient's survival.

show abstract

“…[19] 1982-1996 421 NA 11% 5.5 Villejuif [11] 1984-1994 69 NA 9% NA Birmingham [7] 1982-1999 400 4.7 17% 3.0 San Francisco [29] 1988-1996 69 5.3 14% NA Chicago [21] 1984-2000 46 6.8 15% 6.5 Madrid [30] 1986-1999 19 6 …”

Section: Discussionmentioning

confidence: 99%